Which ISO 11607 Packaging Declaration of Conformity Survives 20 December 2026: Why FDA Rec 14-594 and 14-595 Name 2019 Including AMD1:2023, Why Rec 14-530 and 14-531 Remain Acceptable Until That Date, Why Decision (EU) 2024/815 Already Cites EN ISO 11607-1:2020/A1:2023, and Why GB/T 19633.1-2024 Is the 2019 IDT Implemented 1 December 2025

Does ISO 11607-1:2019/Amd 1:2023 publication mean FDA, the EU or China have moved the packaging file?

When international medical-device distributors, private-label OEM buyers, and hospital procurement teams evaluate terminally sterilized single-use devices—such as disposable circumcision rings, anastomat kits, surgical staplers, or sterile injection needles—the packaging dossier is often summarized by a single line on a Certificate of Conformity: 'Sterile barrier packaging validated in accordance with ISO 11607.'¹ In September 2026, that generic sentence creates severe regulatory vulnerability. Over the past three years, the standards landscape governing sterile barrier systems (SBS) has experienced major structural updates across Geneva, Silver Spring, Brussels, and Beijing.¹⁵¹¹¹⁵ However, standard publication by an international standardization committee is legally distinct from statutory recognition by sovereign regulatory authorities.⁵¹⁰¹³

The baseline standard for sterile medical device packaging remains ISO 11607-1:2019 (Packaging for terminally sterilized medical devices — Part 1: Requirements for materials, sterile barrier systems and packaging systems), published in February 2019 by ISO technical committee ISO/TC 198 (Sterilization of health care products).¹ ISO catalogue records for the 2019 second edition remain the current Part 1 and Part 2 publications, each with one amendment titled Application of risk management.¹³ On 13 September 2023, ISO published ISO 11607-1:2019/Amd 1:2023, a 17-page amendment officially titled 'Application of risk management' (stage 60.60).² On the same calendar day, ISO published the parallel Part 2 amendment: ISO 11607-2:2019/Amd 1:2023, also titled 'Application of risk management' (stage 60.60).⁴

Algorithmic search overviews and trade blogs often collapse this chronology into a single inaccurate assertion, claiming that because ISO published Amd 1 in late 2023, unamended 2019 test data became immediately obsolete across global markets. As demonstrated in Table 1, sovereign regulators do not adopt international amendments instantaneously or uniformly.⁵¹¹¹⁵ In the United States, the Food and Drug Administration (FDA) formally recognized the amended 2019 editions under separate Federal Register recognition numbers while granting a multi-year coexistence window for declarations of conformity to the unamended text.⁵⁶ In the European Union, European standards organizations issued EN ISO 11607-1:2020/A1:2023 and EN ISO 11607-2:2020/A1:2023, which the European Commission cited in the Official Journal in March 2024.¹¹¹² In China, SAMR and SAC published GB/T 19633.1-2024, a recommended national standard that the official catalogue records as an identical adoption (等同采用) of ISO 11607-1:2019, implemented 1 December 2025. That catalogue row does not name Amendment 1:2023.¹⁵

Understanding this jurisdictional fragmentation is critical for international device buyers. Just as examined in our analysis of which ISO 10993-7 edition still governs an EO residual CoA, an international buyer cannot rely on general ISO catalogue status to establish statutory compliance.¹⁵ A packaging file that satisfies an EU technical file under an Official Journal citation may still be the wrong US premarket DoC if it fails to cite the recognition number printed on the live FDA Supplementary Information Sheet.⁵¹⁰ This packaging-DoC clock is also distinct from the ISO 15223-1 EU REP symbol acceptance label-symbol clocks.

What do FDA Rec 14-594 and Rec 14-595 name, and why do Rec 14-530 and Rec 14-531 still matter until 20 December 2026?

In the United States, medical device premarket reviews (510(k), De Novo, and PMA) and quality system inspections under the Quality Management System Regulation (QMSR, 21 CFR 820) rely heavily on the FDA CDRH Recognized Consensus Standards database.⁵¹⁰ When an applicant uses a Declaration of Conformity to a recognised consensus standard in a premarket file, that declaration has to name the specific recognition number on the current Supplementary Information Sheet.¹⁰

A search of the FDA Recognized Consensus Standards database for designation number 11607 on 10 September 2026 returns four recognition rows (14-594, 14-530, 14-595, 14-531), with the database page last updated on 25 May 2026.⁹ An independent census of the same database snapshot (1,898 rows, datePublished 26 August 2026) yields the same four Rec numbers for designations containing 11607-1 or 11607-2. FDA Recognition Number 14-585 is ISO/TS 16775 / AAMI TIR16775, an informative guidance document, not a 11607 designation and not a substitute DoC.²⁰

These four active recognition rows represent two paired sets of Part 1 and Part 2 standards:⁵⁶⁷⁸

• FDA Recognition Number 14-594 (Part 1 Amended): Standard Identification Number 44769. Published in Federal Register Recognition List Number 061 with an entry date of 18 December 2023. Standard: ISO 11607-1 Second edition 2019-02 [Including AMD1:2023] Packaging for terminally sterilized medical devices - Part 1: Requirements for materials, sterile barrier systems and packaging systems [Including Amendment 1 (2023)]. Extent of Recognition: Complete standard. Transition text: 'FDA will accept declarations of conformity, in support of premarket submissions, to [Rec# 14-530] until December 20, 2026. After this transition period, declarations of conformity to [Rec# 14-530] will not be accepted.'⁵
• FDA Recognition Number 14-595 (Part 2 Amended): Standard Identification Number 44771. Published in FR List 061 with an entry date of 18 December 2023. Standard: ISO 11607-2 Second edition 2019-02 [Including AMD1:2023] Packaging for terminally sterilized medical devices - Part 2: Validation requirements for forming, sealing and assembly processes [Including Amendment 1 (2023)]. Extent of Recognition: Complete standard. Transition text: 'FDA will accept declarations of conformity, in support of premarket submissions, to [Rec# 14-531] until December 20, 2026. After this transition period, declarations of conformity to [Rec# 14-531] will not be accepted.'⁷
• FDA Recognition Number 14-530 (Part 1 Unamended): Standard Identification Number 44770. Published in FR List 052 with an entry date of 15 July 2019. Standard: ISO 11607-1 Second edition 2019-02, with identical adoption ANSI AAMI ISO 11607-1:2019. Extent of Recognition: Complete standard. Transition text records: superseded by Recognition Number 14-594, with declarations of conformity accepted until 20 December 2026.⁶
• FDA Recognition Number 14-531 (Part 2 Unamended): Standard Identification Number 44772. Published in FR List 052 with an entry date of 15 July 2019. Standard: ISO 11607-2 Second edition 2019-02, with identical adoption ANSI AAMI ISO 11607-2:2019. Extent of Recognition: Complete standard. Transition text records: superseded by Recognition Number 14-595, with declarations of conformity accepted until 20 December 2026.⁸

The operational implication of this database architecture is straightforward: on 10 September 2026, 101 calendar days remain until the 20 December 2026 transition cutoff.⁵⁶ During this 101-day window, a medical device sponsor submitting a 510(k) premarket notification to FDA may submit a Declaration of Conformity citing Rec 14-530 (for Part 1) and Rec 14-531 (for Part 2).⁶⁸ The SIS transition sentence is the operational test: those unamended Rec numbers remain acceptable DoC citations until 20 December 2026.⁵¹⁰

However, beginning on 21 December 2026, FDA CDRH review staff will no longer accept declarations of conformity citing Rec 14-530 or Rec 14-531.⁵⁷ Any premarket notification submitted on or after 21 December 2026 that relies on a Declaration of Conformity for sterile packaging must cite Rec 14-594 and Rec 14-595, which requires the manufacturer's packaging documentation to encompass ISO 11607-1:2019/Amd 1:2023 and ISO 11607-2:2019/Amd 1:2023.⁵⁷ If a supplier hands a distributor a packaging validation report citing only the unamended 2019 standard for a US device program targeted for submission in early 2027, the distributor will face an immediate administrative deficiency unless the supplier completes the Amendment 1 risk-management documentation overlay.²⁵

Is the 20 December 2026 clock a warehouse-lot withdrawal or a premarket declaration-of-conformity window?

A widespread panic observed among medical device distributors and hospital supply-chain managers is the misconception that the 20 December 2026 date represents a commercial 'sunset date' or mandatory product recall for finished sterile devices.⁵ Under this erroneous interpretation, any sterile single-use device currently resting in a commercial warehouse whose packaging was validated prior to Amd 1:2023 would become illegal to distribute or sell on 21 December 2026.⁵

This panic misinterprets the statutory authority of the FDA Supplementary Information Sheet (SIS).⁵¹⁰ The exact text published on the SIS for Rec 14-594 and Rec 14-530 states: 'FDA will accept declarations of conformity, in support of premarket submissions, to recognition number 14-530 until December 20, 2026.'⁵⁶ Notice the precise limiting phrase: 'in support of premarket submissions'.⁵

The transition date printed in the Recognized Consensus Standards database applies exclusively to the administrative validity of a Declaration of Conformity submitted during premarket review.⁵¹⁰ It does not, on its face, invalidate an existing 510(k) clearance, cancel a labelled shelf life, require retrospective re-testing of distributed product, or force warehouse lots off the market.⁵ A later packaging, material or process change can still require a new premarket filing for its own reasons; that is a change-control question, not the 20 December 2026 DoC sentence.¹⁰

As detailed in our QMSR production and process-control file review, FDA postmarket enforcement under 21 CFR 820 focuses on whether the manufacturer adheres to validated process parameters and design controls recorded in the Device Master Record (DMR) and Device History Record (DHR). The SIS sentence does not convert warehouse stock manufactured under an unamended 2019 protocol into an automatic inspection observation.⁵¹⁰ What the printed clock does control is a new premarket Declaration of Conformity after 20 December 2026 that still cites Rec 14-530 or Rec 14-531.⁵⁷

Why is Part 2 Rec 14-595 / Rec 14-531 a separate incoming check from Part 1?

A frequent audit failure during incoming supplier qualification is treating ISO 11607 as a single monolithic standard.¹³ A buyer will receive a vendor compliance binder containing an extensive test report demonstrating that Tyvek® lidding material meets ASTM F88 tensile peel-strength requirements and that microbial barrier properties comply with ISO 11607-1.¹⁵ The supplier declares conformity to Rec 14-594, and the buyer's quality engineer checks the box. This check is fundamentally incomplete.³⁷

ISO 11607-1 and ISO 11607-2 govern entirely different engineering domains:¹³

• ISO 11607-1 (Materials, SBS, and Packaging Systems): Governs requirements and test methods for materials, preformed sterile barrier systems, sterile barrier systems and packaging systems intended to maintain sterility of terminally sterilized medical devices until the point of use.¹ In the US, Part 1 is recognized under Rec 14-594 (amended) and Rec 14-530 (unamended).⁵⁶
• ISO 11607-2 (Validation Requirements for Forming, Sealing, and Assembly Processes): Governs development and validation of forming, sealing and assembly processes for packaging that is terminally sterilized.³ Incoming inspection still needs process-validation evidence from the legal manufacturer or contract packager on the actual production line, not only a materials certificate from a rollstock converter.³ In the US, Part 2 is recognized under Rec 14-595 (amended) and Rec 14-531 (unamended).⁷⁸

A packaging material supplier or rollstock converter can provide compliance documentation only for ISO 11607-1.¹ The converter cannot validate the medical device manufacturer's heat-sealing machine, form-fill-seal platen, or tray sealer.³ The actual medical device legal manufacturer or contract packaging facility must perform and document the forming, sealing, and assembly validation required by ISO 11607-2 on the actual production line.³

Furthermore, an incoming quality inspector must not accept an ISO 11135 sterilization cycle certificate as a substitute for ISO 11607-2 sealing validation.³ As detailed in our guide to ISO 11135 ethylene-oxide cycle validation acceptance, an ISO 11135 certificate addresses the ethylene-oxide sterilization cycle, not the sterile-barrier materials file or the forming/sealing validation.³ Cycle lethality does not prove that the seal remained intact through sterilizer vacuum and pressure transitions.¹³

Similarly, citing ISO/TS 16775 (FDA Rec 14-585) does not close the packaging file.²⁰ The SIS states that ISO/TS 16775 is an informative document, does not add to or change the requirements of ISO 11607-1 and ISO 11607-2, and is not required to demonstrate conformity with them.²⁰ An incoming audit checklist must demand distinct evidence deliverables for both Part 1 and Part 2.⁵⁷

What did Decision (EU) 2024/815 add, and why is that not the FDA December 2026 clock?

In the European Union, the legal mechanism for standards conformity differs fundamentally from the US FDA consensus recognition system.¹¹¹³ Under the Union harmonised-standards system, devices that comply with relevant harmonised standards whose references have been published in the Official Journal of the European Union enjoy a presumption of conformity with the corresponding requirements those standards aim to cover.¹¹¹³ ISO catalogue publication is not that Official Journal citation.¹³

On 6 March 2024, the European Commission adopted Commission Implementing Decision (EU) 2024/815, published in the Official Journal on 8 March 2024 (OJ L 815).¹¹ Article 2 of Decision 2024/815 stipulated that the decision entered into force on the exact day of its publication in the Official Journal.¹¹ The Annex to Decision 2024/815 amended the master MDR harmonisation decision, Commission Implementing Decision (EU) 2021/1182, by inserting rows 23 and 24:¹¹¹²

• Annex Row 23: 'EN ISO 11607-1:2020 Packaging for terminally sterilized medical devices - Part 1: Requirements for materials, sterile barrier systems and packaging systems (ISO 11607-1:2019)', accompanied by 'EN ISO 11607-1:2020/A1:2023'.¹¹¹²
• Annex Row 24: 'EN ISO 11607-2:2020 Packaging for terminally sterilized medical devices - Part 2: Validation requirements for forming, sealing and assembly processes (ISO 11607-2:2019)', accompanied by 'EN ISO 11607-2:2020/A1:2023'.¹¹¹²

A parallel implementing act, Commission Implementing Decision (EU) 2024/817, was adopted on the same date for IVD devices under Regulation (EU) 2017/746 and added EN ISO 11607-1:2020/A1:2023 and EN ISO 11607-2:2020/A1:2023 as items 12 and 13 of Decision (EU) 2021/1195.¹⁴ The consolidated MDR annex (CELEX 02021D1182-20260617, updated through 17 June 2026) still lists rows 23 and 24; the extract used for this review did not contain a date-of-withdrawal cell for those 11607 rows.¹²

This European regulatory fact highlights a vital distinction: the European Union does not share FDA's 20 December 2026 transition date.⁵¹¹ The US date is the SIS DoC window printed on Rec 14-594/14-530 and Rec 14-595/14-531.⁵⁷ In Europe, EN ISO 11607-1:2020/A1:2023 and EN ISO 11607-2:2020/A1:2023 have been cited in the Official Journal since 8 March 2024, so presumption of conformity follows that OJ reference rather than FDA's December 2026 calendar.¹¹¹³ The extract of the consolidated 2021/1182 annex used for this review did not print an EU analogue of 20 December 2026 for the unamended EN 2020 text.¹² Treating the US premarket DoC cutoff as a Union CE-marking withdrawal date misreads both instruments.⁵¹¹

What should a China-bound file show under GB/T 19633.1-2024, and why is that not Amd 1:2023 by default?

For devices manufactured, registered or imported into China, packaging evidence has to match the national standard actually cited in the registered file, not a foreign Rec number or OJ citation.¹⁵ GB/T 19633.1-2024 is a recommended national standard (推荐性), not a mandatory GB, on the official catalogue.¹⁵

The governing recommended national standard for terminally sterilized medical device packaging in China is GB/T 19633.1-2024 (Packaging for terminally sterilized medical devices — Part 1: Requirements for materials, sterile barrier systems and packaging systems / 最终灭菌医疗器械包装 第1部分：材料、无菌屏障系统和包装系统的要求).¹⁵ The official SAMR national-standard catalogue record establishes the following administrative parameters:¹⁵

• Standard Status: Active and in-force (现行).¹⁵
• Issue Date: Published on 28 May 2024 by SAMR and the Standardization Administration of China (SAC).¹⁵
• Implementation Date: Formally implemented on 1 December 2025.¹⁵
• Competent Authority: National Medical Products Administration (国家药品监督管理局).¹⁵
• International Equivalence: Identical adoption (等同采用) of ISO 11607-1:2019. The catalogue row does not name Amd 1:2023.¹⁵

This standard replaces GB/T 19633.1-2015 in full.¹⁵ The essential boundary for a buyer file is narrower than a process story: the official catalogue records identical adoption of ISO 11607-1:2019 and does not name Amendment 1:2023.²¹⁵ That is not proof NMPA rejected Amd 1, and it is not proof the 2024 GB includes it. Until a later catalogue row says otherwise, a China-bound file should cite GB/T 19633.1-2024 as the 2019 identical adoption identified here.¹⁵

Where a registered Product Technical Requirement (PTR / 产品技术要求) cites GB/T 19633.1-2024, the China-bound packaging report should follow that national standard rather than a US Rec number or an EU OJ citation.¹⁵ Rec 14-594 and Decision (EU) 2024/815 are not Chinese packaging law.⁵¹¹¹⁵ For forming, sealing and assembly, the parallel recommended national standard is GB/T 19633.2-2024, implemented on the same 1 December 2025 date as an identical adoption of ISO 11607-2:2019.¹⁹ Table 2 compares the packaging-file test across the three jurisdictions.

Does Amd 1 require new F88, F1929 or F1980 testing, or is it a risk-management documentation overlay?

When device manufacturers and converters learn that FDA Recognition 14-594 incorporates Amendment 1:2023, a frequent operational reaction is to assume that all existing packaging validation data must be repeated.²⁵ Laboratories and consulting firms often encourage this assumption, offering costly revalidation packages that re-run ASTM F88 seal peel strength, ASTM F1929 dye penetration, ASTM F2096 bubble emission, and ASTM F1980 accelerated aging.²

A careful reading of the official standard identity refutes this assumption: Amendment 1:2023 is titled 'Application of risk management'.² It is not titled 'Revised seal strength requirements' or 'New microbial challenge testing'.² As established in our comprehensive ISO 11607-1 and ISO 11607-2 packaging validation, aging and lot-release tests guide, the published Amd 1 title does not announce a new seal-strength, dye-penetration or aging protocol. The 17-page amendment was not purchased, so this page does not claim that every test method is unchanged at clause level.¹²

What the public identity of Amendment 1:2023 supports is a risk-management documentation overlay, not a new physical-test table.²⁴ The 17-page Part 1 amendment is paywalled; this page does not quote sample-size or sealing-window tables from that text. For incoming inspection, the practical request is that packaging failure modes sit in the ISO 14971 file rather than remaining isolated in a converter binder:²

• Packaging risk analysis in the master file: Ask whether packaging failure modes (seal delamination, pinholes, abrasion, puncture from device edges, loss of integrity in distribution) are mapped into the device ISO 14971 risk-management file, rather than remaining only in a packaging-engineering binder.² The 2019 second edition already added usability evaluation for aseptic presentation; Amd 1 is titled Application of risk management, not usability, as distinguished in our sterile-device recall evidence and supplier-control map.
• Rationale, not a new F88 table: Ask for the documented rationale that connects seal-strength limits, integrity-test selection and sample size to the severity of loss of sterility. That is a documentation request, not a demand to repeat valid 2019 physical data.²⁴
• Part 2 process risk: Ask whether forming/sealing Operational Qualification still names worst-case process windows. Do not treat Amd 1 as an automatic scrap-and-revalidate of a statistically justified IQ/OQ/PQ that already meets the 2019 second edition.⁴
• Honest limit: These incoming questions follow the published Amd 1 title and the FDA Rec 14-594/14-595 edition identity. They are not a clause-level extract of the paywalled 17-page amendment.²⁵

Consequently, if a medical device manufacturer already holds a packaging validation file that demonstrates valid seal strength, whole-package integrity, distribution challenge, and shelf-life data meeting ISO 11607-1:2019, the physical test data is not automatically expired by Amd 1's title.¹² The manufacturer is not, on the public catalogue, required to re-run a completed aging study merely because Rec 14-594 names AMD1:2023. What a US-bound premarket file still needs after 20 December 2026 is a Declaration of Conformity that cites Rec 14-594 and Rec 14-595, plus documented risk-management overlay in the ISO 14971 risk-management file.²⁵ Table 3 is an incoming-inspection split between 2019 physical protocols and the Amd 1 documentation request; it is not a scraped test table from the amendment.

Worked examples: a CE-marked EO circumcision blister versus an NMPA-only sterile needle versus an SKU with no sterilisation method in the public product data, and why NOVACURE is out of scope

To demonstrate how these multi-jurisdictional standards and recognition clocks operate in commercial supply chains, consider four distinct product configurations from the VEMERIX minimally invasive surgery portfolio.¹⁶¹⁷¹⁸ Each product illustrates a specific packaging compliance pathway and highlights critical boundaries where commercial assumptions must not outpace primary regulatory evidence.⁵¹¹¹⁵

• Worked Example 1: VEMERIX Circumcision Device (CE-Marked EO Blister SKU): The disposable Circumcision Device (Adult and Children types) is an NMPA Class II registered device that carries a European CE mark.¹⁶ Public product data records ethylene-oxide sterilisation and individual sterile blister packaging.¹⁶ It does not name Tyvek, paper lidding, or a tray geometry. For export to European Union member states, the packaging technical documentation should cite EN ISO 11607-1:2020/A1:2023 and EN ISO 11607-2:2020/A1:2023 under Decision (EU) 2024/815 if the manufacturer relies on OJ presumption of conformity.¹¹¹² If targeted for a US premarket submission, the declaration of conformity may cite Rec 14-530 and Rec 14-531 until 20 December 2026, or Rec 14-594 and Rec 14-595 thereafter.⁵⁶⁷⁸ Citing an unamended 2019 certificate on a US submission after that date is the SIS deficiency.⁵
• Worked Example 2: VEMERIX Disposable Circumcision Stapler (Factory EO Sterilized, No CE Claim): Registered under NMPA Lu Mech Reg. 20192020192, the Disposable Circumcision Stapler is documented in public product data as 'Factory EO sterilized' and does not carry a European CE mark.¹⁷ Public product data also does not name a packaging configuration. Commercial distribution within China is governed by the registered Product Technical Requirement and, where that PTR cites them, GB/T 19633.1-2024 and GB/T 19633.2-2024.¹⁵¹⁷¹⁹ Do not invent a European MDR harmonisation or apply US FDA Rec 14-594 to a Chinese domestic batch release.⁵¹⁵
• Worked Example 3: VEMERIX Sterile Single-Use Injection Needle (NMPA Class III, No CE Field): The sterile single-use injection needle is an NMPA Class III medical device presented for aesthetic and hydrofacial workflows.¹⁸ The public specification records a sterile single-use format and does not record a European CE mark, a sterilisation modality, or a packaging configuration.¹⁸ Packaging evidence for Chinese domestic procurement should follow GB/T 19633.1-2024 where the PTR cites it, and must not inherit FDA Rec 14-594, Decision (EU) 2024/815, or an invented ethylene-oxide close-out.¹⁵⁵¹¹
• Worked Example 4: Single-Use Medical Laser Fiber (1470 nm): Registered under NMPA Lu Mech Reg. 20192010517, the medical laser fiber is described as single-use, sterile and individually packed.²¹ The public product specification does not name an ethylene oxide or other specific sterilisation modality. Demanding an ISO 11607 packaging validation tied to EO gas ingress invents a process not established on the public record. Until a specific terminal sterilisation modality is formally documented, the fiber cannot inherit an EO packaging close-out.²¹
• Scope Boundary: NOVACURE Diode Laser System: The NOVACURE 1470 nm diode laser system is a partner-supplied capital console used in conjunction with Medison's registered single-use fiber. The console is non-sterile capital electronic equipment, not a sterile consumable. It is out of scope for ISO 11607 packaging validation and is omitted from related products.

Distributor and OEM incoming checklist: edition on the DoC, Rec 14-594/14-595 versus 14-530/14-531, EN A1:2023, GB/T 19633.1-2024, Part 1 plus Part 2, and the documents to request

To prevent customs holds, notified body non-conformities, and premarket submission rejection, international distributor quality departments and OEM private-label brand owners should deploy a structured 7-Gate Incoming Sterile Packaging Acceptance Checklist.⁵¹¹¹⁵ When receiving a supplier's packaging dossier or batch release binder, systematically audit the documentation against the parameters set out in Table 5.

Where VEMERIX fits—and where buyer due diligence still begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care.¹⁶ For terminally sterilized urological consumables—including the CE-marked disposable Circumcision Device (Adult and Children types) and the factory EO-sterilized Disposable Circumcision Stapler—distributors and procurement partners can request the current packaging validation summaries, sterilization cycle records, and regulatory declarations.¹⁶¹⁷

Professional technical partnership requires a clear limit: VEMERIX does not claim a published, SKU-level Amd 1 packaging-file close-out, and does not claim that every export shipment already carries Rec 14-594 and Rec 14-595. The live instruments a buyer should match to the destination file are US FDA Recognition Numbers 14-594 and 14-595 (with Rec 14-530 and 14-531 still acceptable as premarket DoC until 20 December 2026), European Commission Implementing Decision (EU) 2024/815 (EN ISO 11607-1:2020/A1:2023 and Part 2/A1:2023), and Chinese GB/T 19633.1-2024 (with GB/T 19633.2-2024 for process validation).^57111519

Buyer due diligence begins by verifying that the cited standard edition, recognition number, and risk-management documentation on the packaging declaration correspond to the target market's premarket or commercial clearance requirements.⁵¹⁰ International medical device distributors, OEM brand owners, and regulatory affairs managers can request the current packaging pack through our Quality page, review the product portfolio, or contact the team via Contact.

Frequently Asked Questions

Q1: Is ISO 11607-1:2019 without Amd 1 still acceptable as an FDA declaration of conformity on 10 September 2026?
Yes. As of 10 September 2026, FDA still accepts Declarations of Conformity in support of premarket submissions to Recognition Number 14-530 (ISO 11607-1:2019 unamended, identical adoption ANSI AAMI ISO 11607-1:2019) and Recognition Number 14-531 (ISO 11607-2:2019 unamended). That transition period remains open until 20 December 2026 (101 calendar days remaining). After 20 December 2026, declarations of conformity to those unamended Rec numbers will not be accepted.⁵⁶⁷⁸

Q2: Does Rec 14-594 also cover ISO 11607-2 forming, sealing and assembly validation?
No. FDA Recognition Number 14-594 covers only ISO 11607-1 (materials, sterile barrier systems, and packaging systems). Process validation for forming, sealing, and assembly equipment (IQ/OQ/PQ) is governed by ISO 11607-2, which is recognized separately under FDA Recognition Number 14-595 (or Rec 14-531 until 20 December 2026). A complete packaging submission must cite both recognition numbers.⁵⁷

Q3: Does Amd 1:2023 require the factory to repeat seal-strength and dye-penetration protocols?
No. Amendment 1:2023 is titled 'Application of risk management'. The public catalogue title is Application of risk management, not a revised F88, F1929 or F1980 table. Existing valid physical test data is not automatically expired by that title. A US-bound premarket DoC after 20 December 2026 still has to cite Rec 14-594 and Rec 14-595, with documented risk-management overlay rather than a demand to repeat a completed 2019 aging study.¹²

Q4: If a lot is already on a distributor shelf, does 20 December 2026 make that lot unsalable?
No. The 20 December 2026 transition date applies strictly to declarations of conformity submitted in support of new premarket submissions (510(k), De Novo, PMA). It is not a product recall, shelf-life cancellation, or commercial sales ban. Devices manufactured and cleared under legally compliant 510(k)s may continue to be distributed and used throughout their labeled sterile shelf life.⁵¹⁰

Q5: Does Decision (EU) 2024/815 mean a 2019-only packaging file still confers MDR presumption of conformity?
No. Commission Implementing Decision (EU) 2024/815 amended the MDR harmonised standards list by adding EN ISO 11607-1:2020/A1:2023 (item 23) and EN ISO 11607-2:2020/A1:2023 (item 24) on 8 March 2024. Presumption of conformity follows that Official Journal citation, not ISO publication. The annex extract used for this review did not print an EU analogue of 20 December 2026 for the unamended EN 2020 text.¹¹¹²¹³

Q6: Does GB/T 19633.1-2024 include ISO 11607-1:2019/Amd 1:2023?
The official SAMR catalogue records GB/T 19633.1-2024 (implemented 1 December 2025) as an identical adoption (等同采用) of ISO 11607-1:2019 and does not name Amendment 1:2023. That is not proof NMPA rejected Amd 1, and it is not proof the 2024 GB includes it. China-bound compliance should be shown against GB/T 19633.1-2024 and the device's registered Product Technical Requirement (PTR).¹⁵

Q7: Does an ISO 11135 or ISO/TS 16775 citation close the packaging file?
No. ISO 11135 is the ethylene-oxide cycle-validation sibling, not the sterile-barrier DoC. ISO/TS 16775 is informative guidance (FDA Rec 14-585); the SIS states it does not add to ISO 11607-1 or ISO 11607-2 and is not required to demonstrate conformity with them. A complete packaging file still needs Part 1 and Part 2 declarations matched to the destination Rec, EN or GB citation.³⁵⁷²⁰

Q8: Does VEMERIX already hold a published Amd 1 packaging-file close-out for these SKUs?
No. This page does not claim a published, SKU-level Amd 1 close-out. Buyers should request the current packaging pack and match the edition plus Rec, EN or GB citation on the DoC to the destination file, for both Part 1 and Part 2.⁵¹¹¹⁶